Increased activity of the metalloproteinase PAPP-A promotes diabetes-induced glomerular hypertrophy
Diabetic nephropathy (DN) is a serious complication of diabetes and a common cause of end stage renal failure. Insulin-like growth factor (IGF)-signaling has been implicated in DN, but is mechanistically poorly understood. Here, we assessed the activity of the metalloproteinase PAPP-A, an activator of IGF activity, and its possible interaction with the endogenous PAPP-A inhibitors stanniocalcin (STC)-1 and -2 in the mammalian kidney under normal and hyperglycemic conditions.
Source: Metabolism - Clinical and Experimental - Category: Biomedical Science Authors: Malene R. Jepsen, Jakob A. Østergaard, Cheryl A. Conover, Lise Wogensen, Henrik Birn, Søren P. Krag, Robert A. Fenton, Claus Oxvig Source Type: research
More News: Biomedical Science | Diabetes | Endocrinology | Insulin | Renal Failure | Urology & Nephrology